(1) an increase to the Company’s authorized shares of common stock, par value $0.0001 (“Common Stock”), from 400,000,000 shares to 10,699,999,990 shares; and
(2) an increase to the Company’s authorized shares of preferred stock, par value $0.0001, from 0 shares to 3,000,010 shares and designation of a Series A class of preferred stock with 10 authorized shares, and a Series B class of preferred stock with 3,000,000 authorized shares.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM